MOESM1 of Secukinumab efficacy on resolution of enthesitis in psoriatic arthritis: pooled analysis of two phase 3 studies

Coates, Laura; Wallman, Johan; McGonagle, Dennis; Schett, Georg; McInnes, Iain; Mease, Philip; Rasouliyan, Lawrence; Quebe-Fehling, Erhard; Asquith, Darren; Fasth, Andreas; Pricop, Luminita; Gaillez, Corine

doi:10.6084/m9.figshare.11321501.v1

13075_2019_2055_MOESM1_ESM.docx (39.34 kB)

MOESM1 of Secukinumab efficacy on resolution of enthesitis in psoriatic arthritis: pooled analysis of two phase 3 studies

journal contribution

posted on 2019-12-05, 05:30 authored by Laura Coates, Johan Wallman, Dennis McGonagle, Georg Schett, Iain McInnes, Philip Mease, Lawrence Rasouliyan, Erhard Quebe-Fehling, Darren Asquith, Andreas Fasth, Luminita Pricop, Corine Gaillez

Additional file 1: Table S1. Unadjusted efficacy outcome measures in patients with or without enthesitis at baseline.

Funding

Novartis Pharma AG

History

Usage metrics

Keywords

Psoriatic arthritis Enthesitis Secukinumab Interleukin 17A inhibitor Anti-TNF Biologics

Licence

CC BY + CC0

Exports

RefWorks

BibTeX

Ref. manager

Endnote

DataCite

NLM

DC

MOESM1 of Secukinumab efficacy on resolution of enthesitis in psoriatic arthritis: pooled analysis of two phase 3 studies

Funding

Novartis Pharma AG

History

Usage metrics

Categories

Keywords

Licence

Exports